Ra Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM
Retrieved on:
Wednesday, December 4, 2019
The randomized, double-blind, placebo-controlled, multi-center, Phase 2 clinical trial will evaluate the safety, tolerability, and efficacy of zilucoplan in patients with IMNM who are positive for anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) or anti-signal recognition particle (SRP) autoantibodies.
Key Points:
- The randomized, double-blind, placebo-controlled, multi-center, Phase 2 clinical trial will evaluate the safety, tolerability, and efficacy of zilucoplan in patients with IMNM who are positive for anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) or anti-signal recognition particle (SRP) autoantibodies.
- Patients will be randomized in a 1:1 ratio to receive daily subcutaneous (SC) doses of 0.3 mg/kg zilucoplan or placebo.
- Following completion of the trial, patients will have the option to enter into an open-label long-term extension study with zilucoplan.
- With both the Phase 2 clinical trial in IMNM and the Phase 3 clinical trial in gMG now underway, weve taken important steps in our efforts to bring innovative and accessible therapies to patients with rare, complement-mediated diseases.